Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Astria Therapeutics Q3 EPS $(0.55) Misses $(0.41) Estimate, Sales $706.000K.

Author: Benzinga Newsdesk | November 12, 2025 08:06am

Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.41) by 34.8 percent. This is a 30.95 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $706.000 thousand. 

Posted In: ATXS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist